News

A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…

One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…

While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications like Bylvay (odevixibat) and Livmarli…

Babies who had standard Kasai surgery when they were more than 60 days old or had spleen malformations were more likely to have poor outcomes…

A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…

A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…

Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic target, a study showed. Deteriorating…

Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…

The U.S. Food and Drug Administration (FDA) has conditionally approved Novo Nordisk’s Wegovy (semaglutide) to treat certain people with metabolic dysfunction-associated steatohepatitis (MASH), a…

Current approaches to hepatitis B care across the globe are failing to adequately connect patients with treatment, and also to retain them for long-term…